Aviceda Therapeutics

About Aviceda Therapeutics

Aviceda Therapeutics is a company focused on harnessing the body's natural immune system to modulate inflammation through highly selective ligands designed for maximum specificity towards target immune cells and diseases.

Products & Services

Pipeline and Programs:Details about therapeutic programs and development pipeline are available, though specific products are not listed in the content.

Specialties

Immune system modulation Inflammation treatment Selective ligand design

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series C T: - FT: Series C	A: 207500000 MR: - FA: $207.5 million FAN: 207500000	D: 2025-01-07 FD: 2025-01-07	12 investors

Series C Latest

2025-01-07

$207.5M

12 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

J

Jeffrey Nau

President & CEO

D

David Callanan

Chief Medical Officer & Senior Vice-President

D

Derek Kunimoto

Chief Strategy Officer, Head of Clinical Development & Co-Founder

T

Tarek S. Hassan

Chief Development Officer & Senior Vice-President

M

Matthew Barrows

Senior Vice President, Chemistry, Manufacturing, and Control (CMC) & Technical Operations

A

Anitha Krishnan

Executive Director, Research

View 25 more team members with Pro

Unlock Full Team Directory

Recent News